Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
From Seaside to Bedside: Dedicated to Professor José María Fernández...
share announcement

From Seaside to Bedside: Dedicated to Professor José María Fernández Sousa-Faro

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 6594

Special Issue Editors

Dr. Carmen Cuevas

E-Mail
Guest Editor
Research & Development Area, Pharmamar S.A. Pol. Ind. La Mina Norte, Avda. de los Reyes 1, 28770 Colmenar Viejo, Spain
Interests: marine natural products
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Fernando Albericio

E-Mail Website
Guest Editor
1. School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa
2. Department of Organic Chemistry, University of Barcelona, Barcelona, Spain
Interests: antimicrobial peptides; solid-phase chemistry; combinatorial chemistry; drug delivery systems; peptide drug conjugates; orthogonal chemistry; drug discovery; biomaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Professor José María Fernández Sousa-Faro has a degree in Chemistry (1967) and a doctorate in Biochemistry (1971) from Universidad Complutense, Madrid. Between 1971 and 1979, he was a tenured professor and subsequently held the position of Chair of Biochemistry at the University of Santiago de Compostela. He received an Honorary Doctorate from Universidad Antonio de Nebrija (Madrid) and was awarded Spain’s National Biotechnology Prize, both in 2009.

Between 1967 and 1979, he worked at the following institutions: Institut für Physikalische Chemie at the University of Basel (Switzerland), Department of Molecular Biology at Washington University in Saint Louis, Missouri (USA),  L’Institut de Biologie Physico-Chimique at Fondation Edmond de Rothschild in Paris (France), and the research laboratories of ICI Pharmaceuticals Division, Alderley Edge, and Shell in Sittingbourne (UK).

He has over 100 academic publications and patents in the fields of biochemistry, molecular biology, and anti-infective and anti-tumor drugs, and a worldwide reputation.

Between 1979 and 1985, Professor Fernández Sousa-Faro was Research Director at Antibióticos S.A.

In 1986, Professor Fernández Sousa-Faro founded PharmaMar S.A. in Spain, as a unique pioneering company with an international presence, inspired by marine exploration to discover novel medicines, first for oncology and more recently for fighting viral infections. 

PharmaMar S.A. was the first company in the world to market a marine-derived anticancer drug and has successfully brought three marine-derived drugs to the oncology market, Yondelis® (trabectedin), Zepzelca® (lurbinectedin), and Aplidin® (plitidepsin), with several more in clinical development as part of its discovery pipeline.

Professor Fernández Sousa-Faro has been, and continues to be, a visionary about the impact of science in society; “The sea is the inspiration, the science is the motor, and the patients are the motivation”.

Professor Fernández Sousa-Faro has successfully pioneered multiple successful private–public partnerships and created a network of hundreds of collaborators across the five continents.

In this Special Issue of Marine Drugs, his scientific collaborators, but also friends, want to pay tribute to the scientist, the entrepreneur, and the remarkable man, Professor José María Fernández Sousa-Faro.

Dr. Carmen Cuevas
Prof. Dr. Fernando Albericio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine natural products
  • marine pharmacology
  • marine-derived drugs
  • anti-infective drugs
  • anti-tumor drugs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 4189 KiB  
Article
Regulation of Safracin Biosynthesis and Transport in Pseudomonas poae PMA22
by J. Gerardo Hernández Delgado, Miguel G. Acedos, Fernando de la Calle, Pilar Rodríguez, José Luis García and Beatriz Galán
Mar. Drugs 2024, 22(9), 418; https://doi.org/10.3390/md22090418 - 13 Sep 2024
Viewed by 1114
Abstract
Pseudomonas poae PMA22 produces safracins, a family of compounds with potent broad-spectrum anti-bacterial and anti-tumor activities. The safracins’ biosynthetic gene cluster (BGC sac) consists of 11 ORFs organized in two divergent operons (sacABCDEFGHK and sacIJ) that are controlled by Pa [...] Read more.
Pseudomonas poae PMA22 produces safracins, a family of compounds with potent broad-spectrum anti-bacterial and anti-tumor activities. The safracins’ biosynthetic gene cluster (BGC sac) consists of 11 ORFs organized in two divergent operons (sacABCDEFGHK and sacIJ) that are controlled by Pa and Pi promoters. Contiguous to the BGC sac, we have located a gene that encodes a putative global regulator of the LysR family annotated as MexT that was originally described as a transcriptional activator of the MexEF-OprN multidrug efflux pump in Pseudomonas. Through both in vitro and in vivo experiments, we have demonstrated the involvement of the dual regulatory system MexT-MexS on the BGC sac expression acting as an activator and a repressor, respectively. The MexEF-OprN transport system of PMA22, also controlled by MexT, was shown to play a fundamental role in the metabolism of safracin. The overexpression of mexEF-oprN in PMA22 resulted in fourfold higher production levels of safracin. These results illustrate how a pleiotropic regulatory system can be critical to optimizing the production of tailored secondary metabolites, not only through direct interaction with the BGC promoters, but also by controlling their transport. Full article
(This article belongs to the Special Issue From Seaside to Bedside: Dedicated to Professor José María Fernández Sousa-Faro)
►▼ Show Figures

Graphical abstract

11 pages, 1357 KiB  
Article
From Sea Sponge to Clinical Trials: Starting the Journey of the Novel Compound PM742
by Patricia G. Cruz, Rogelio Fernández, Raquel Rodríguez-Acebes, Marta Martínez-Díez, Gema Santamaría-Núñez, Marta Pérez and Carmen Cuevas
Mar. Drugs 2024, 22(8), 339; https://doi.org/10.3390/md22080339 - 26 Jul 2024
Viewed by 2628
Abstract
PM742 (1), a new chemical entity, has been isolated from the sponge Discodermia du Bocage collected in the Pacific Ocean. This compound showed strong in vitro cytotoxicity against several human tumor cell lines as well as a tubulin depolymerization mechanism of [...] Read more.
PM742 (1), a new chemical entity, has been isolated from the sponge Discodermia du Bocage collected in the Pacific Ocean. This compound showed strong in vitro cytotoxicity against several human tumor cell lines as well as a tubulin depolymerization mechanism of action, which led us to conduct an extensive Structure-Activity-Relationship study through the synthesis of different analogs. As a result, a derivatively named PM534 (2) is currently in its first human Phase I clinical trial. Herein, we present a comprehensive review of the isolation, structural elucidation, and antitumor activities of the parent compound PM742. Full article
(This article belongs to the Special Issue From Seaside to Bedside: Dedicated to Professor José María Fernández Sousa-Faro)
►▼ Show Figures

Graphical abstract

13 pages, 1539 KiB  
Article
Cellulamides: A New Family of Marine-Sourced Linear Peptides from the Underexplored Cellulosimicrobium Genus
by Mariana Girão, José Murillo-Alba, Jesús Martín, Ignacio Pérez-Victoria, Ricardo B. Leite, Ralph Urbatzka, Pedro N. Leão, Maria F. Carvalho and Fernando Reyes
Mar. Drugs 2024, 22(6), 268; https://doi.org/10.3390/md22060268 - 11 Jun 2024
Viewed by 1622
Abstract
Bioprospecting the secondary metabolism of underexplored Actinomycetota taxa is a prolific route to uncover novel chemistry. In this work, we report the isolation, structure elucidation, and bioactivity screening of cellulamides A and B (1 and 2), two novel linear peptides obtained [...] Read more.
Bioprospecting the secondary metabolism of underexplored Actinomycetota taxa is a prolific route to uncover novel chemistry. In this work, we report the isolation, structure elucidation, and bioactivity screening of cellulamides A and B (1 and 2), two novel linear peptides obtained from the culture of the macroalga-associated Cellulosimicrobium funkei CT-R177. The host of this microorganism, the Chlorophyta Codium tomentosum, was collected in the northern Portuguese coast and, in the scope of a bioprospecting study focused on its associated actinobacterial community, strain CT-R177 was isolated, taxonomically identified, and screened for the production of antimicrobial and anticancer compounds. Dereplication of a crude extract of this strain using LC-HRMS(/MS) analysis unveiled a putative novel natural product, cellulamide A (1), that was isolated following mass spectrometry-guided fractionation. An additional analog, cellulamide B (2) was obtained during the chromatographic process and chemically characterized. The chemical structures of the novel linear peptides, including their absolute configurations, were elucidated using a combination of HRMS, 1D/2D NMR spectroscopy, and Marfey’s analysis. Cellulamide A (1) was subjected to a set of bioactivity screenings, but no significant biological activity was observed. The cellulamides represent the first family of natural products reported from the Actinomycetota genus Cellulosimicrobium, showcasing not only the potential of less-explored taxa but also of host-associated marine strains for novel chemistry discovery. Full article
(This article belongs to the Special Issue From Seaside to Bedside: Dedicated to Professor José María Fernández Sousa-Faro)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop